Tazobac (2 gm+0.25 gm)/vial (IV Infusion)

Indications

• Treatment of moderate to severe infections caused by susceptible isolates of designated bacteria
• Intra-abdominal infections
• Skin and skin structure infections
• Female pelvic infections
• Community-acquired pneumonia
• Nosocomial pneumonia

Pharmacology

• Bactericidal activity against gram-positive and gram-negative bacteria
• Inhibition of septum and cell wall synthesis
• Enhancement and extension of antibiotic spectrum

Dosage & Administration

• Administered by intravenous infusion over 30 minutes
• Usual total daily dose for adults and pediatric patients
• Different dosage for nosocomial pneumonia
• Dosage adjustment for pediatric patients with renal impairment

Interaction

• Inactivation of aminoglycosides
• Sequential administration with tobramycin
• Probenecid prolongs half-life
• Effects on coagulation parameters
• Prolongation of neuromuscular blockade
• Competition for renal secretion with methotrexate

Contraindications

• Allergic reactions to penicillins, cephalosporins, or β-lactamase inhibitors

Side Effects

• Skin-related adverse events
• Gastrointestinal adverse events
• General disorders and administration site conditions
• Immune hypersensitivity reactions
• Metabolism and nutrition disorders
• Musculoskeletal and connective tissue disorders
• Psychiatric disorders
• Vascular disorders
• Respiratory, thoracic, and mediastinal disorders

Pregnancy & Lactation

• Crosses placenta in humans
• Insufficient data on drug-associated risk for major birth defects and miscarriage
• Excretion in human milk
• Effects on the breastfed child and milk production

Precautions & Warnings

• Serious hypersensitivity reactions
• Severe cutaneous adverse reactions
• Hematological effects
• Nephrotoxicity in critically ill patients
• Clostridium difficile associated diarrhea

Use in Special Populations

• Pediatric use
• Geriatric use
• Renal impairment
• Hepatic impairment
• Patients with cystic fibrosis

Overdose Effects

• Nausea, vomiting, and diarrhea
• Neuromuscular excitability or convulsions
• Supportive and symptomatic treatment

Therapeutic Class

• Broad spectrum penicillins
• Other beta-lactam antibiotics

Reconstitution

• Reconstitution details for intravenous infusion
• Storage instructions before and after reconstitution

Storage Conditions

• Temperature and environmental storage considerations

Related Brands

• Brodactam (2 gm+0.25 gm)/vial (IV Infusion) - synovia-pharma-plc
• Tazocilin (2 gm+0.25 gm)/vial (IV Infusion) - square-pharmaceuticals-plc
• Tazocin (4 gm+0.5 gm)/vial (IV Infusion) - pfizer
• Tazopen (2 gm+0.25 gm)/vial (IV Infusion) - renata-limited
• Tazobac (4 gm+0.5 gm)/vial (IV Infusion) - aci-limited